Kytril

Chemotherapy, Operative Surgery, Nausea + 1 more

Treatment

3 FDA approvals

20 Active Studies for Kytril

What is Kytril

Granisetron

The Generic name of this drug

Treatment Summary

Ondansetron is a medication used to prevent nausea and vomiting in cancer patients undergoing chemotherapy. It works by blocking the action of serotonin, a chemical messenger in the brain that can trigger nausea and vomiting.

Kytril

is the brand name

Kytril Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Kytril

Granisetron

1993

63

Approved as Treatment by the FDA

Granisetron, also known as Kytril, is approved by the FDA for 3 uses such as Nausea and vomiting and Nausea .

Nausea and vomiting

Nausea

Chemotherapy

Effectiveness

How Kytril Affects Patients

Granisetron is a drug that targets serotonin receptors, specifically type 3 serotonergic receptors. It does not affect other serotonin receptors, nor does it have an effect on blood pressure, heart rate, or electrocardiogram (ECG). It works similarly to another drug called ondansetron. When chemotherapy drugs are used, they may damage the lining of the digestive tract and cause the release of serotonin. This serotonin stimulates certain nerves in the brain, leading to nausea and vomiting. Granisetron works by blocking serotonin receptors to prevent this reaction.

How Kytril works in the body

Granisetron works by blocking serotonin receptors that are present in the brain and stomach. Blocking these receptors prevents them from sending signals to the area of the brain responsible for vomiting, reducing the risk of nausea and vomiting.

When to interrupt dosage

The proposed portion of Kytril is contingent upon the determined disorder, for instance Nausea, Radiation Therapy and Operative Surgery. The amount of dosage fluctuates, as per the method of delivery (e.g. Solution - Oral or Injection, solution) detailed in the following table.

Condition

Dosage

Administration

Operative Surgery

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Subcutaneous, Injection - Subcutaneous, Liquid - Intravenous, Solution - Oral, Liquid

Radiation Therapy

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Subcutaneous, Injection - Subcutaneous, Liquid - Intravenous, Solution - Oral, Liquid

Chemotherapy

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Subcutaneous, Injection - Subcutaneous, Liquid - Intravenous, Solution - Oral, Liquid

Nausea

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Subcutaneous, Injection - Subcutaneous, Liquid - Intravenous, Solution - Oral, Liquid

Warnings

There are 20 known major drug interactions with Kytril.

Common Kytril Drug Interactions

Drug Name

Risk Level

Description

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Anagrelide.

Apomorphine

Major

The risk or severity of hypotension can be increased when Granisetron is combined with Apomorphine.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Asenapine.

Kytril Toxicity & Overdose Risk

The lowest toxic dose of this drug in rats has been found to be greater than 2000mg/kg when taken orally.

image of a doctor in a lab doing drug, clinical research

Kytril Novel Uses: Which Conditions Have a Clinical Trial Featuring Kytril?

85 active trials are currently being conducted to investigate the potential of Kytril to mitigate Nausea, Operative Surgery and Radiation Therapy.

Condition

Clinical Trials

Trial Phases

Operative Surgery

71 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 1, Phase 2, Early Phase 1

Radiation Therapy

6 Actively Recruiting

Not Applicable, Phase 3, Early Phase 1

Nausea

0 Actively Recruiting

Chemotherapy

4 Actively Recruiting

Phase 1, Phase 3, Not Applicable

Kytril Reviews: What are patients saying about Kytril?

5

Patient Review

5/5/2010

Kytril for Nausea and Vomiting

This drug was a life-saver for me when I was going through chemotherapy. It completely alleviated my nausea and vomiting. I would highly recommend it to anyone else undergoing cancer treatment.

5

Patient Review

11/20/2008

Kytril for Prevent Nausea and Vomiting from Cancer Chemotherapy

This drug helped control my nausea much more than anything else I have tried. I still had no appetite but did not feel nauseous or vomit at all.

5

Patient Review

11/17/2009

Kytril for Nausea and Vomiting

This treatment has been essential for me and I can't imagine living without it.

5

Patient Review

9/18/2009

Kytril for Prevent Nausea and Vomiting from Cancer Chemotherapy

This treatment is effective.

5

Patient Review

11/18/2009

Kytril for Prevent Nausea and Vomiting from Cancer Chemotherapy

This was the only treatment that helped me with my severe vomiting and nausea when I was pregnant with my daughter. It allowed me to lead a normal life, which was a huge relief.

5

Patient Review

7/18/2020

Kytril for Nausea and Vomiting caused by Cancer Drugs

Super effective!

4.7

Patient Review

5/6/2010

Kytril for Prevent Nausea and Vomiting from Cancer Chemotherapy

This treatment has been a lifesaver. I don't know what I would do without it.

4

Patient Review

11/18/2008

Kytril for Nausea and Vomiting caused by Cancer Drugs

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about kytril

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Kytril the same as Zofran?

"Glaxo's Zofran and SmithKline Beecham's Kytril are both effective in controlling chemotherapy-induced nausea and vomiting in lung cancer patients at the recommended doses."

Answered by AI

What does Kytril treat?

"This drug is used to prevent vomiting and nausea caused by cancer treatments like chemotherapy and radiation therapy. It works by blocking out serotonin, one of the body's chemicals that causes vomiting."

Answered by AI

How long does Kytril take to work?

"In the ferret animal model, a single injection of granisetron prevented vomiting due to high-dose cisplatin, or stopped vomiting within 5 to 30 seconds. In most human studies, granisetron has had little effect on blood pressure, heart rate or ECG."

Answered by AI

When should I take Kytril?

"The dosage of KYTRIL tablets for the prevention of nausea and vomiting associated with chemotherapy is typically one 2 mg tablet once a day, taken within one hour before the start of chemotherapy. This dosage may be taken for up to one week following chemotherapy."

Answered by AI

Clinical Trials for Kytril

Image of Washington University / Barnes Jewish Hospital in St Louis, United States.

AI-Driven Clinical Decision Support for Surgery

18+
All Sexes
St Louis, MO

20 million patients have surgery in the United States every year, with approximately 1 million of those patients requiring life-saving blood transfusion. Presurgical preparation for transfusion is important to allow for safe and timely transfusion during surgery; however, excessive preparation is unfortunately common, costly, and contributes to blood waste. This study aims to evaluate an intelligent clinical decision support system that helps clinicians prepare blood for patients who are likely to need it, while avoiding excessive preparation for patients who don't, potentially improving patient safety while reducing blood waste and healthcare costs.

Recruiting
Has No Placebo

Washington University / Barnes Jewish Hospital

Image of UPMC Hillman Cancer Center in Pittsburgh, United States.

Mobile App for Cancer

18+
All Sexes
Pittsburgh, PA

The goal of this study is to determine whether a mobile application that combines real-time sensor data and patient-reported symptoms to trigger care-team contact recommendations is feasible and beneficial for patients receiving chemotherapy. The main questions it aims to answer are: * Is the mobile application feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment? Participants will: * Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * Complete daily symptom ratings via study application. * Wear a Fitbit activity tracker for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study. * Optional: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).

Waitlist Available
Has No Placebo

UPMC Hillman Cancer Center

Carissa A Low

Image of UPMC Shadyside Hospital in Pittsburgh, United States.

Bright Green Light Therapy for Postoperative Pain

18+
All Sexes
Pittsburgh, PA

This is an unblinded, parallel group randomized controlled trial to evaluate bright green light as an adjunct therapy after surgery at UPMC Shadyside. The primary outcome measure will be pain intensity with secondary outcome measures including opioid requirements, sleep quality, mood, and overall post-operative recovery. Specific aims/hypotheses for this study are as follows: Aim 1: To assess bright green light therapy's potential as a complementary post-operative analgesic strategy in patients recovering from surgery Hypothesis 1: Participants exposed to bright green light, in comparison to dim white (ambient) light, will have improved postoperative pain scores and lower opioid use. Aim 2: To examine the impact of bright green light therapy on patient-centered measures of post-operative recovery that may be related to improved circadian function. Hypothesis 2: Participants exposed to bright green light, in comparison to dim white (ambient) light, will have improved quality of post-operative recovery, enhanced sleep, and reduced anxiety and depression.

Waitlist Available
Has No Placebo

UPMC Shadyside Hospital

Rebecca Kotcher, MD

Have you considered Kytril clinical trials?

We made a collection of clinical trials featuring Kytril, we think they might fit your search criteria.
Go to Trials
Image of Walter Reed National Military Medical Center in Bethesda, United States.

Corticosteroid Injections for Osteoarthritis

18+
All Sexes
Bethesda, MD

The goal of this clinical trial is to find out which type of steroid medicine, when added to a standard pain-control injection during total knee replacement surgery, works best at reducing pain, limiting opioid use, and improving recovery in adults undergoing surgery for severe knee arthritis or injury. The main questions it aims to answer are: Does adding a steroid to the injection improve pain control and reduce opioid use after surgery? Is the newer extended-release steroid (Zilretta) more effective and safer-especially for patients with diabetes-than the traditional steroid (methylprednisolone)? Researchers will compare: Standard pain-control injection alone Standard injection plus methylprednisolone Standard injection plus Zilretta to see which option provides better pain relief, less opioid use, and improved knee function. (Patients with diabetes or prediabetes will only be in the standard injection or Zilretta groups so researchers can study whether Zilretta is safer for blood sugar control.) Participants will: Be randomly assigned to one of the study groups during their total knee replacement surgery Receive the assigned pain-control injection around the knee joint Be followed after surgery to measure: Pain levels Opioid pain medication use Knee movement (range of motion) Whether another procedure (such as manipulation under anesthesia) is needed if the knee becomes too stiff Patient-reported outcome surveys about pain and function

Phase 2 & 3
Waitlist Available

Walter Reed National Military Medical Center

John P Cody, MD

Have you considered Kytril clinical trials?

We made a collection of clinical trials featuring Kytril, we think they might fit your search criteria.
Go to Trials
Image of UC Davis Dermatology in Sacramento, United States.

Ethyl Chloride Spray for Pain Reduction in Surgery

18+
All Sexes
Sacramento, CA

Fear of needles is a well-documented issue that affects many patients. This fear may cause significant anxiety in various medical situations, including in the dermatology office 1. If not properly managed, needle phobia can persist, affecting a patient's experience during each visit. This effect may compound and lead to avoidance behaviors that can delay necessary treatments 2. This issue is particularly relevant in a Mohs micrographic surgery (MMS) clinic where each patient experiences several painful needle injections before the day is over. Ethyl chloride is gaining popularity among dermatologists for its routine use in clinical practice due to its anesthetic and antiseptic properties, especially as a pre-injection agent. Research indicates that cryotherapy or pre-cooling the skin before administering a local anesthetic may offer benefits over topical anesthetics, such as enhanced pain relief, quicker onset, and better patient compliance 3,4. However, to our knowledge, no studies have specifically examined the effectiveness of pre-cooling with ethyl chloride prior to Mohs micrographic surgery. To address this gap, we're conducting a trial aimed at evaluating the impact of pre-cooling with ethyl chloride on pain perception in adult patients undergoing Mohs micrographic surgery with local anesthetic injections. The trial is a single-center, split-body study. The split-body design will involve dividing the surgical site into two equal halves, with one half (right side relative to patient) designated as the treatment side (receiving ethyl chloride spray prior to lidocaine injection) and the other as the control side (no ethyl chloride spray prior to injection). During the procedure, the participant will be asked to rate the pain associated with the needle injection AND the pain from infiltration of anesthetic from each side of the wound using the visual analog scale (VAS) scoring system (1 = no pain, 10 = most amount of pain possible). The results of the study will help us better understand how to mitigate pain and anxiety for patients requiring MMS.

Phase < 1
Recruiting

UC Davis Dermatology

Image of CHU de Québec-Université Laval (Hôpital de l'Enfant-Jésus) in Québec, Canada.

Lidocaine + Dexmedetomidine for Surgery Outcomes

18+
All Sexes
Québec, Canada

Up to 40% of patients experience suboptimal recovery in the days following major surgery, limiting their return to functional independence. Few preventive interventions exist, but intravenous dexmedetomidine and lidocaine administered during general anesthesia represent simple strategies that may significantly impact recovery and other patient-centred outcomes after surgery. The goal of this pilot trial is to determine the feasibility of conducting a phase 3 pragmatic adaptive multicentre trial to evaluate the impact of dexmedetomidine and lidocaine administered during major non-cardiac surgery on patient-centred outcomes.

Recruiting
Has No Placebo

CHU de Québec-Université Laval (Hôpital de l'Enfant-Jésus)

Michael Verret, MD PhD FRCPC

Image of University Health Network in Toronto, Canada.

Sleep Prehabilitation for Surgery

18+
All Sexes
Toronto, Canada

The goal of this clinical trial is to learn if changing sleep behaviour can improve sleep health in patients undergoing prehabilitation before elective surgery. Prehabilitation is the use of exercise, nutrition, and psychological support before surgery to improve recovery from surgery. The main questions it aims to answer are: Does changing sleep behaviour improve sleep before surgery? Does changing sleep behaviour improve recovery after surgery? Researchers will compare participants who receive sleep support with participants who do not receive sleep support to see if it improves sleep health and recovery from surgery. Participants will be asked to attend 4 meetings with the research team to learn how they can improve their sleep. They will use questionnaires, a diary, and a wearable tracker to record their sleep.

Recruiting
Has No Placebo

University Health Network

Ian Randall, MD

Have you considered Kytril clinical trials?

We made a collection of clinical trials featuring Kytril, we think they might fit your search criteria.
Go to Trials